^
    Back
    Association details:
    Biomarker:HER-2 exon 20 YVMA insertion
    Cancer:Lung Adenocarcinoma
    Drug:Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) +
    Exkivity (mobocertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Cancer Res
    Title:

    Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

    Published date:
    10/15/2021
    Excerpt:
    HER2 exon 20 YVMA insertion tumors showed a potent and sustained response to the combination of mobocertinib and ado-trastuzumab emtansine (T-DM1).
    DOI:
    10.1158/0008-5472.CAN-21-1526